Techedge, Inc. Appoints Dr. Shu as CEO and Chief Scientist for China BioPharma
Tuesday April 4, 8:55 am ET
ISELIN, N.J.--(BUSINESS WIRE)--April 4, 2006--Techedge, Inc. (OTCBB:TEDG - News) today announced its appointment of Dr. Jean-Denis Shu (MD, MBA) as the CEO and Chief Scientist of its soon to be wholly owned subsidiary China BioPharma Limited.
ADVERTISEMENT
On February 13, 2006, Techedge, Inc. announced that it had signed a letter of intent to acquire China BioPharma Limited, a Cayman island Company, which has the rights to have majority ownership in one of the largest non-governmental owned vaccine development and manufacturing companies in China. The company's currently available products are vaccines against Influenza and Epidemic Hemorrhagic Fever. Techedge is in the process of preparing the legal document and expect to close this deal in Q2, 2006.
Formerly the Regional Director of Far East & North Pacific of Chiron Vaccines, Dr. Shu is widely recognized as a vaccine expert in China, with extensive experiences in business start-ups and general management in vaccine industry, proven track-record in medical and marketing management in France and China, and strong resource network. His past professional experiences also include General Delegate China for Aventis Pasteur, and Medical and Regulatory Affairs Manager for Pasteur Merieux Connaught, based in Lyon, France. Dr Shu was the author of several articles and books in vaccines.
A French citizen born in Shanghai, Dr. Shu is bi-cultural and tri-lingual (English, French and Chinese). He earned a Certificate of Finance and Accounting from Wharton School, a MBA from the European School of Management (ESCP-EAP) in Paris, a Diploma of Specialization on Gynecology-Obstetrics from Medical and Pharmacy College of Besancon in France, and a Medical Degree, B. Med. from Medical University of Shanghai II, in China. Dr Shu spent five years as Foreign Physician in French hospitals.
"As a witness and player, my career in vaccine industry has developed for ten years together with the growth of Chinese vaccine market that is one of the world fastest growing markets. I am very excited about this opportunity and am committed to lead China BioPharma to become a leading market player in China's enormous vaccine and bio-pharmaceutical industry", commented Dr. Shu.
